Health Ltp Fund General Par... Net Worth

The estimated Net Worth of Health Ltp Fund General Par... is at least 6.12 百万$ dollars as of 5 July 2022. Health Par owns over 8,738,243 units of Seres Therapeutics Inc stock worth over 6,116,770$ and over the last 2 years Health sold MCRB stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Health Par MCRB stock SEC Form 4 insiders trading

Health has made over 1 trades of the Seres Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Health bought 8,738,243 units of MCRB stock worth 27,525,465$ on 5 July 2022.

The largest trade Health's ever made was buying 8,738,243 units of Seres Therapeutics Inc stock on 5 July 2022 worth over 27,525,465$. On average, Health trades about 8,738,243 units every 0 days since 2022. As of 5 July 2022 Health still owns at least 5,825,495 units of Seres Therapeutics Inc stock.

You can see the complete history of Health Par stock trades at the bottom of the page.

Insiders trading at Seres Therapeutics Inc

Over the last 9 years, insiders at Seres Therapeutics Inc have traded over 37,132,594$ worth of Seres Therapeutics Inc stock and bought 17,627,131 units worth 47,525,463$ . The most active insiders traders include Noubar Afeyan、Health Ltp Fund General Par...、Health Science Us Holdings,.... On average, Seres Therapeutics Inc executives and independent directors trade stock every 35 days with the average trade being worth of 251,393$. The most recent stock trade was executed by Thomas Des Rosier on 15 August 2024, trading 2,656 units of MCRB stock currently worth 2,789$.

What does Seres Therapeutics Inc do?

seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.

Complete history of Health Par stock trades at Seres Therapeutics Inc

Seres Therapeutics Inc executives and stock owners

Seres Therapeutics Inc executives and other stock owners filed with the SEC include:

• Eric Shaff,
  President, Chief Executive Officer, Director
• Eric D. Shaff M.B.A.,
  Pres, CEO & Director
• Thomas DesRosier,
  Chief Legal Officer, Executive Vice President and Secretary
• Matthew Henn,
  Executive Vice President, Chief Scientific Officer
• Thomas J. DesRosier,
  Chief Legal Officer, Exec. VP & Sec.
• Dr. David S. Ege Ph.D.,
  Exec. VP & Chief Technology Officer
• Richard Kender,
  Independent Director
• Kurt Graves,
  Independent Director
• Meryl Zausner,
  Independent Director
• Willard Dere,
  Independent Director
• Gregory Behar,
  Independent Director
• Dennis Ausiello,
  Independent Director
• Stephen Berenson,
  Independent Chairman of the Board
• David Ege,
  Executive Vice President, Chief Technology Officer
• Jayne Gansler,
  Chief People Officer, Executive Vice President
• Terri Young,
  Executive Vice President, Chief Commercial and Strategy Officer
• Lisa von Moltke,
  Executive Vice President, Chief Medical Officer
• Paul Biondi,
  Independent Director
• Carlo Tanzi,
  Head of Investor Relations and Corporate Communications
• John Aunins,
  Executive Vice President of Bioprocess & Manufacturing and Chief Technology Officer
• Marcus Chapman,
  Senior Vice President - Finance and Principal Financial and Accounting Officer
• Dr. John G. Aunins Ph.D.,
  Sr. Advisor
• Dr. Matthew R. Henn Ph.D.,
  Exec. VP & Chief Scientific Officer
• David A. Arkowitz M.B.A.,
  Exec. VP, CFO & Head of Bus. Devel.
• James R. Weston,
  Sr. VP of Regulatory Affairs
• Jayne M. Gansler,
  Exec. VP & Chief People Officer
• Jeff York,
  VP of HR
• Noubar Flagship Ventures Fu...,
  
• Peter Barton Hutt,
  Director
• Michele Trucksis,
  See Remarks
• David N Cook,
  See Remarks
• Noubar Afeyan,
  Director
• Health Science Us Holdings,...,
  
• Lorence H. Kim,
  Director
• Wael Hashad,
  EVP & Chief Commercial Officer
• Teresa L. Young,
  See Remarks
• Paula Cloghessy,
  See Remarks
• Marella Thorell,
  See Remarks
• Roger Pomerantz,
  President and CEO
• Kevin Horgan,
  Chief Medical Officer and EVP
• Werner Cautreels,
  Director
• Noubar Flagship Ventures Fu...,
  
• Ventures Fund Iv General Pa...,
  
• Health Ltp Fund General Par...,
  
• David Arkowitz,
  Chief Financial Officer
• Health Ltp Fund General Par...,
  
• Claire Fraser,